Drug–drug interaction comparison between tacrolimus and phenobarbital in different formulations for paediatrics and adults. (3rd August 2021)

• Record Type: Journal Article
• Authors: Zhao, Xianmei; Lu, Xiaoqing; Zuo, Meiling; Wang, Nan; Zhang, Yuan; Chen, Jingtao; Zhu, Liqin; Liu, Wei
• Is Part Of: Xenobiotica. Volume 51:Number 8(2021)
• Page Start: 877
• Page End: 884
• Publication Date: 2021-08-03
• Subjects: Tacrolimus -- phenobarbital -- pharmacokinetics -- drug-drug interaction -- PBPK model; Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.1080/00498254.2021.1943564
• Languages: English
• ISSNs: 0049-8254

Abstract

Abstract: To compare drug–drug interaction (DDI) between tacrolimus and different formulations of phenobarbital in paediatrics and adults. Physiologically based pharmacokinetics (PBPK) models were used to evaluate DDI between phenobarbital (oral (p.o.) and intravenous (i.v.) formulations) and tacrolimus in paediatrics and adults. All dosing regimens were maintained for 7 days. Compared to i.v. phenobarbital, p.o. phenobarbital could decrease pharmacokinetic (PK) parameters of tacrolimus much more in both paediatrics and adults. On day 7, the results showed that the ratio of Cmax for tacrolimus in the presence and absence of phenobarbital were 0.13 (p.o.) and 0.48 (i.v.), respectively, in paediatrics, while 0.54 (p.o.) and 0.73 (i.v.) in adults, respectively. The ratios of the area under the concentration–time curve (AUC) were 0.06 (p.o.) and 0.18 (i.v.) in paediatrics, while 0.46 (p.o.) and 0.53 (i.v.) in adults, respectively. PK parameters of tacrolimus decreased more significantly in paediatrics compared to adults. In paediatric, phenobarbital had a greater impact on PK of tacrolimus than that in adults. P.o. phenobarbital reduced PK parameters of tacrolimus even more than i.v. administration. In clinical practice, the concentration monitoring and dosage adjustment of tacrolimus should be emphasised when co-administrated with phenobarbital, especially in paediatric or in p.o. formulation. Key points: The results indicated that p.o. and i.v. phenobarbital both had a significant DDI with tacrolimus in paediatrics and adults. Phenobarbital had a greater impact on the PK of tacrolimus over time in paediatrics. P.o. administration of phenobarbital can reduce the PK parameters of tacrolimus more.